Rahman Irfan
Respiratory Medicine, ELEGI Laboratory, MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK.
J Biochem Mol Biol. 2003 Jan 31;36(1):95-109. doi: 10.5483/bmbrep.2003.36.1.095.
Inflammatory lung diseases are characterized by chronic inflammation and oxidant/antioxidant imbalance. The sources of the increased oxidative stress in patients with chronic inflammatory lung diseases such as asthma and chronic obstructive pulmonary disease (COPD) derive from the increased burden of inhaled oxidants, and from the increased amounts of reactive oxygen species (ROS) generated by several inflammatory, immune and various structural cells of the airways. Increased levels of ROS produced in the airways is reflected by increased markers of oxidative stress in the airspaces, sputum, breath, lungs and blood in patients with lung diseases. ROS, either directly or via the formation of lipid peroxidation products such as 4-hydroxy-2-nonenal may play a role in enhancing the inflammation through the activation of stress kinases (JNK, MAPK, p38) and redox sensitive transcription factors such as NF-capital KJE, MacedonianB and AP-1. Recent evidences have indicated that oxidative stress and pro-inflammatory mediators can alter nuclear histone acetylation/deacetylation allowing access for transcription factor DNA binding leading to enhanced pro-inflammatory gene expression in various lung cells. Understanding of the mechanisms of redox signaling, NF-kappaB/AP-1 regulation, the balance between histone acetylation and deacetylation and the release and expression of pro- and antiinflammatory mediators may lead to the development of novel therapies based on the pharmacological manipulation of antioxidants in lung inflammation and injury. Antioxidants that have effective wide spectrum activity and good bioavailability, thiols or molecules which have dual antioxidant and anti-inflammatory activity, may be potential therapeutic agents which not only protect against the direct injurious effects of oxidants, but may fundamentally alter the underlying inflammatory processes which play an important role in the pathogenesis of chronic inflammatory lung diseases.
炎症性肺病的特征是慢性炎症以及氧化/抗氧化失衡。在诸如哮喘和慢性阻塞性肺疾病(COPD)等慢性炎症性肺病患者中,氧化应激增加的来源既包括吸入氧化剂负担的增加,也包括气道的多种炎症、免疫和各种结构细胞产生的活性氧(ROS)数量的增加。气道中产生的ROS水平升高反映在肺病患者的气腔、痰液、呼出气体、肺和血液中氧化应激标志物的增加上。ROS可直接或通过形成脂质过氧化产物(如4-羟基-2-壬烯醛),通过激活应激激酶(JNK、MAPK、p38)和氧化还原敏感转录因子(如NF-κB、MacedonianB和AP-1)在增强炎症方面发挥作用。最近的证据表明,氧化应激和促炎介质可改变核组蛋白的乙酰化/去乙酰化,使转录因子能够结合DNA,从而导致各种肺细胞中促炎基因表达增强。了解氧化还原信号传导、NF-κB/AP-1调节、组蛋白乙酰化与去乙酰化之间平衡以及促炎和抗炎介质释放与表达的机制,可能会基于对肺炎症和损伤中抗氧化剂的药理操作开发出新的治疗方法。具有有效广谱活性和良好生物利用度的抗氧化剂、具有双重抗氧化和抗炎活性的硫醇或分子,可能是潜在的治疗剂,它们不仅可以抵御氧化剂的直接损伤作用,还可能从根本上改变在慢性炎症性肺病发病机制中起重要作用的潜在炎症过程。